In this thirteenth video, the fifth from the afternoon breakout survivorship sessions, GRACE presents Exercise for Lung Cancer Patients, with Jeffrey Eagan DPT.
In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.
In this eleventh video from the Targeted Therapies in Lung Cancer Patient Forum, the third from the afternoon breakout survivorship sessions, GRACE presents Chemo Brain, with Denise Damek, MD.
In this tenth video, the second from the afternoon breakout survivorship sessions, GRACE presents the Cancer Kitchen, with Lisa Wingrove, RD, CSO. Lisa is joined in this video by her lovely kitchen helper, Chris Draft.
In this ninth video from the webcast series, GRACE presents the breakout survivorship session - Bankruptcy and Workplace Discrimination with Patricia McMahon and Carlos Colon, AFC.
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Medical Director at Memorial Cancer Institute, Clinical Associate Prof. of Medicine at FL International University provides an update regarding current immunotherapy agents in development for lung cancer.
It’s #GivingTuesday and we're out to win up to $50,000 in the Newman’s Own Foundation $500k Holiday Challenge. Help GRACE so we can continue to help others!
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a single...
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a single...
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
GRACE Founder and President Dr. H. Jack West gives thanks to immunotherapies that offer new hope to his patients. November is Lung Cancer Awareness Month. What are you grateful for?
With the Thanksgiving holiday in November, the month has become synonymous with gratitude in the U.S. November is also Lung Cancer Awareness Month; an initiative started in 1995 to increase knowledge of the disease.
Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.